BG
PRTK

Bollard Group’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Bollard Group’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,159
Closed -$6K – 428
2022
Q1 		$6K Hold
2,159
– – ﹤0.01% 417
2021
Q4 		$10K Hold
2,159
– – ﹤0.01% 413
2021
Q3 		$10K Hold
2,159
– – ﹤0.01% 408
2021
Q2 		$15K Hold
2,159
– – ﹤0.01% 401
2021
Q1 		$15K Hold
2,159
– – ﹤0.01% 404
2020
Q4 		$14K Hold
2,159
– – ﹤0.01% 402
2020
Q3 		$12K Sell
2,159
-6,814
-76% -$33.7K ﹤0.01% 406
2020
Q2 		$47K Buy
+8,973
New +$39.9K ﹤0.01% 354

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Bollard Group's PRTK Position: Q2 2022 in Review

Bollard Group sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 2,159 shares — an estimated $6K sold.

Bollard Group first reported a position in PRTK in Q2 2020 and held it in 8 quarters. The position peaked at $47K in Q2 2020. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

  • Bollard Group reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 2,159 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $6K.
  • Bollard Group first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Paratek Pharmaceuticals, Inc. position peaked at $47K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.